# Hypercholesterolaemia FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/hypercholesterolaemia

> 6 upcoming FDA catalysts in hypercholesterolaemia: Leqvio (inclisiran sodium, NVS) on Apr to Jul 2027 (topline data readout); Leqvio (inclisiran sodium, NVS) on April 2027 (primary completion); laroprovstat/rosuvastatin 1 (AZN) on May to Aug 2027 (topline data readout); laroprovstat/rosuvastatin 1 (AZN) on May 2027 (primary completion); and 2 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Apr to Jul 2027 | [Leqvio (inclisiran sodium) topline data readout](https://sec-api.dev/pdufa/inclisiran) | NVS | Hypercholesterolaemia | scheduled | "NCT07610278 (A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-04-28 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07610278)) |
| April 2027 | [Leqvio (inclisiran sodium) primary completion](https://sec-api.dev/pdufa/inclisiran) | NVS | Hypercholesterolaemia | scheduled | "NCT07610278 (A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-04-28 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07610278)) |
| May to Aug 2027 | [Laroprovstat/rosuvastatin 1 topline data readout](https://sec-api.dev/pdufa/laroprovstat-rosuvastatin-1) | AZN | Hypercholesterolaemia | scheduled | "NCT07619118 (A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Rosuvastatin on LDL-C in Patients With Hypercholesterolaemia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-05-28 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07619118)) |
| May 2027 | [Laroprovstat/rosuvastatin 1 primary completion](https://sec-api.dev/pdufa/laroprovstat-rosuvastatin-1) | AZN | Hypercholesterolaemia | scheduled | "NCT07619118 (A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Rosuvastatin on LDL-C in Patients With Hypercholesterolaemia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-05-28 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07619118)) |
| Jul to Oct 2027 | [Laroprovstat topline data readout](https://sec-api.dev/pdufa/laroprovstat) | AZN | Hypercholesterolaemia | scheduled | "NCT07619131 (A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07-30 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07619131)) |
| July 2027 | [Laroprovstat primary completion](https://sec-api.dev/pdufa/laroprovstat) | AZN | Hypercholesterolaemia | scheduled | "NCT07619131 (A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07-30 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07619131)) |

## Drugs

- [Leqvio (inclisiran sodium)](https://sec-api.dev/pdufa/inclisiran) (NVS)
- [Laroprovstat/rosuvastatin 1](https://sec-api.dev/pdufa/laroprovstat-rosuvastatin-1) (AZN)
- [Laroprovstat](https://sec-api.dev/pdufa/laroprovstat) (AZN)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/hypercholesterolaemia.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Hypercholesterolaemia FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/hypercholesterolaemia

```bibtex
@misc{secapidev_indications_hypercholesterolaemia_20261116,
  title        = {Hypercholesterolaemia FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/hypercholesterolaemia}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_hypercholesterolaemia_20261116","title":"Hypercholesterolaemia FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/hypercholesterolaemia","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
